IVIXF.US Invion Limited

Healthcare Pharmaceuticals USA Stocks
0.0369 USD
Close of Nov 15, 2026
0.0369 0.0369
Market cap
USD 4.08M
P/E
-
P/B
1.82x
ROE
-105.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is IVIXF.US undervalued?

Graham number

The Graham number of Invion Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Invion Limited fundamental analysis

No fundamental analysis for Invion Limited yet.

Invion Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Invion Limited

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial…

Full company profile